Argenx Soars on Latest Trial Success for Autoimmune Drug Vyvgart
Argenx SE’s shares jumped after the European biotech reported the latest large, successful trial for its blockbuster drug Vyvgart.
This is a summary aggregated from Bloomberg Markets. Read the complete article on the original site:
Read full article at Bloomberg Markets
